| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash provided by financing activities | 3,662 | 388 |
| Net decrease in cash, cash equivalents and restricted cash and cash equivalents | -45,606 | -33,724 |
| Cash and cash equivalents at beginning of period | 112,215 | - |
| Cash and cash equivalents at end of period | 66,609 | - |
Werewolf Therapeutics, Inc. (HOWL)
Werewolf Therapeutics, Inc. (HOWL)